Abstracts tagged "patient outcomes"

Abstract Number: 1804 • 2017 ACR/ARHP Annual Meeting
Patient-Reported Outcomes and Damage Predict Mortality in Lupus
Desiree R Azizoddin¹, Meenakshi Jolly², Patricia P. Katz³ and Edward H. Yelin⁴, ¹Department of Psychology, Loma Linda University, Loma Linda, CA, ²Rush, Chicago, IL, ³Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Physician-assessed disease activity and damage predict mortality in systemic lupus erythematosus (SLE). Patient-reported outcomes (PROs) are known predictors of mortality in other chronic diseases,…
Abstract Number: 212 • 2016 ACR/ARHP Annual Meeting
Pegloticase Provides Clinical Benefit in Patients with Chronic Refractory Gout Who Did Not Meet the Clinical Trial Biochemical Definition of Response
Brian F. Mandell¹, Michael Weisman², Anthony Yeo³ and Peter E. Lipsky⁴, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Rheumatology, Cedars-Sinai Medical Center, West Hollywood, CA, ³Horizon Pharma, Lake Forest, IL, ⁴AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Pegloticase is a recombinant uricase conjugated to polyethylene glycol approved for the treatment of chronic refractory gout refractory. The pivotal clinical trials for pegloticase…
Abstract Number: 2515 • 2016 ACR/ARHP Annual Meeting
Patient-Reported Outcomes in Two Randomized, Controlled Trials (RCTs) in Patients with Rheumatoid Arthritis (RA) Treated with Tocilizumab (TCZ) Monotherapy Compared with Methotrexate (MTX) or Adalimumab (ADA)
Vibeke Strand¹, Kathy Lampl², Christine Birchwood³, Jinglan Pei², Katie Tuckwell⁴, Rebecca Finch⁴, Cem Gabay⁵, Arthur Kavanaugh⁶ and Graeme Jones⁷, ¹Stanford University School of Medicine, Palo Alto, CA, ²Genentech, Inc., South San Francisco, CA, ³1 DNA Way, MS# 304, Genentech, Inc., South San Francisco, CA, ⁴Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁵Rheumatology, Department of Rheumatology, Geneva University Hospital, Geneva, Switzerland, ⁶University of California San Diego, La Jolla, CA, ⁷Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
Background/Purpose: Patient-reported outcomes (PROs) are important measures when determining response to therapy in patients with RA. Previous RCTs have shown that TCZ monotherapy is superior…
Abstract Number: 546 • 2016 ACR/ARHP Annual Meeting
Boolean-Based Remission in Rheumatoid Arthritis Using Physician Versus Patient Global Assessment: Differences in Ultrasonographic Disease Activities, Sustainabilities, and Relapse Rates
Gulsen Ozen¹, Ali Ugur Unal², Haner Direskeneli³ and Nevsun Inanc¹, ¹Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ²Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, ³Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: Patient global assessment (PtGA), despite not being exclusively related to disease activity, is included in Boolean-based remission (BR) criteria for RA. This study evaluated…
Abstract Number: 2548 • 2016 ACR/ARHP Annual Meeting
Single 1g Infusion Vs Double 1g Infusion of Rituximab in Rheumatoid Arthritis in a Large Teaching Hospital: Potential Clinical Benefits and Financial Savings
Ben Roberts¹, Alexander Langridge², John Wilkinson³, Elliot Jones⁴, Edward Lea², Ben Hargreaves⁵, David Walker⁶ and Martin Lee³, ¹Rheumatology, Newcastle University, Newcastle, United Kingdom, ²Rheumatology, Freeman Hospital, Newcastle, United Kingdom, ³Freeman Hospital, Newcastle, United Kingdom, ⁴Newcastle University, Newcastle, United Kingdom, ⁵Musculoskeletal Directorate, Newcastle upon Tyne NHS Foundation Trust, Newcastle, United Kingdom, ⁶Rake Lane, Northumbria Healthcare, Newcastle Upon Tyne, United Kingdom
Background/Purpose: Recent trial data from Mariette et al. investigating a single-dose 1g rituximab regimen as opposed to a double-dose 1g rituximab regimen in patients with…
Abstract Number: 854 • 2016 ACR/ARHP Annual Meeting
The Ducas: Proposal for a Digital Ulcer Assessment Score in Scleroderma
Cosimo Bruni¹, Tanaka Ngcozana², Francesca Braschi³, Guya Piemonte⁴, Laura Benelli⁴, Serena Guiducci⁵, Silvia Bellando-Randone³, Jonathan Grotts⁶, Christopher Denton⁷, Daniel E. Furst⁸ and Marco Matucci-Cerinic⁵, ¹Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Firenze, Italy, ²Rheumatology Department, Lower, Royal Free hospital, London, United Kingdom, ³Department of Clinical and Experimental Medicine, Division of Rheumatology, University of Florence, Firenze, Italy, ⁴University of Florence, Florence, Italy, ⁵Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Florence, Italy, ⁶Biostatistics, University of California Los Angeles, Los Angeles, CA, ⁷Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁸Division of Rheumatology, Department of Internal Medicine, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: No objective measure is presently available to assess digital ulcer (DU) in SSc patients apart from “healed/non healed” and experience-based clinical judgment. The aim…
Abstract Number: 2750 • 2016 ACR/ARHP Annual Meeting
Concordance Between Patient and Physician Global Assessment of the Disease in Patients with Psoriatic Arthritis
Josefina Gallino Yanzi¹, Osvaldo Luis Cerda², Margarita Landi², Cecilia Zaffarana², Emilce Schneeberger² and Gustavo Citera¹, ¹Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Rheumatology Section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
Background/Purpose: In Rheumatoid Arthritis it has been observed a significant discrepancy in the global assessment of the disease by the patient and physician and this…
Abstract Number: 889 • 2016 ACR/ARHP Annual Meeting
The Utility of Patient-Reported Outcomes in Predicting Disease Activity in Patients with Takayasu’s Arteritis
Antoine G. Sreih¹, Tanaz A. Kermani², Gunnar Tomasson³, Joshua F. Baker⁴, David Cuthbertson⁵, Renee Borchin⁶, Simon Carette⁷, Lindsy J. Forbess⁸, Gary S. Hoffman⁹, Nader A. Khalidi¹⁰, Curry L. Koening¹¹, Carol A. McAlear¹², Paul A. Monach¹³, Larry W. Moreland¹⁴, Christian Pagnoux¹⁵, Philip Seo¹⁶, Robert F. Spiera¹⁷, Kenneth J. Warrington¹⁸, Steven R. Ytterberg², Carol A. Langford¹⁹ and Peter A. Merkel²⁰, ¹Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Dept of Public Health Sciences, University of Iceland, Reykjavik, IS, ⁴Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁵Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁶University of South Florida, Tampa, FL, ⁷Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁸Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁹Rheumatology, Cleveland Clinic, Cleveland, OH, ¹⁰Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ¹¹Rheumatology, University of Utah, Salt Lake City, UT, ¹²University of Pennsylvania, Philadelphia, PA, ¹³Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁴Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹⁵Division of Rheumatology, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, Canada, Toronto, ON, Canada, ¹⁶Medicine, Johns Hopkins University, Baltimore, MD, ¹⁷Hospital for Special Surgery, Cornell, New York, NY, ¹⁸Rheumatology, University of California Los Angeles, CA, USA Mayo, Rochester, MN, ¹⁹Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²⁰Division of Rheumatology, Univ of Pennsylvania; Perelman School of Med, Philadelphia, PA
Background/Purpose: Takayasu’s arteritis (TAK) is a relapsing large vessel vasculitis. There are currently no reliable predictors of disease relapse. This study explored whether changes in…
Abstract Number: 3179 • 2016 ACR/ARHP Annual Meeting
Scale Structure and Measurement Properties of a Disease Specific Patient-Reported Outcome for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Joanna C. Robson^1,2,3, Jill Dawson⁴, Judy A. Shea⁵, Helen Doll⁶, Susan Ashdown⁷, Renee Borchin⁸, Ebony Easley⁹, John T. Farrar¹⁰, Don Gebhart¹¹, Katherine Kellom¹², Georgia Lanier¹³, Raashid Luqmani¹⁴, Carol A McAlear¹⁵, John Mills¹⁶, Nataliya Milman^17,18,19, Jacqueline Peck⁷, Gunnar Tomasson²⁰, Peter F. Cronholm⁹ and Peter A. Merkel²¹, ¹Faculty of Health and Applied Science, University of the West of England, Bristol, United Kingdom, ²Department of Rheumatology, University Hospitals Bristol NHS Trust, Bristol, United Kingdom, ³School of Clinical Sciences, University of Bristol, Bristol, United Kingdom, ⁴Nuffield Department of Population Health HSRU, University of Oxford, Oxford, United Kingdom, ⁵Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, ⁶Department of Population Health, University of East Anglia, Norwich, United Kingdom, ⁷Oxford, Oxford, United Kingdom, ⁸University of South Florida, Tampa, FL, ⁹Department of Family Medicine and Community Health, The University of Pennsylvania, Philadelphia, PA, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Columbus, Columbus, OH, ¹²PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, United Kingdom, ¹³NONE, Framingham, MA, ¹⁴NDORMS , Rheumathology, Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ¹⁵Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁶Vasculitis UK, Sheffield, United Kingdom, ¹⁷Department of Medicine, University of Ottawa, Ottawa, ON, Canada, ¹⁸The Ottawa Hospital, Ottawa, ON, Canada, ¹⁹Department of Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, ON, Canada, ²⁰Dept of Public Health Sciences, University of Iceland, Reykjavik, IS, ²¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Candidate questionnaire items were produced following in-depth qualitative research in the UK, US, and Canada plus cognitive interviews, extensive piloting and independent linguistic and…
Abstract Number: 890 • 2016 ACR/ARHP Annual Meeting
Health-Related Domains of Importance to Patients with Takayasu’s Arteritis
Antoine G. Sreih¹, Fatma Alibaz-Oner², Ebony Easley³, Trocon Davis³, Gonca Mumcu⁴, Nataliya Milman⁵, Joanna C. Robson⁶, Peter F. Cronholm³, Haner Direskeneli⁷ and Peter A. Merkel⁸, ¹Rheumatology, The University of Pennsylvania, Philadelphia, PA, ²Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ³Department of Family Medicine and Community Health, The University of Pennsylvania, Philadelphia, PA, ⁴Department of Health Management, Marmara University, Faculty of Health Sciences, Istanbul, Turkey, ⁵Department of Medicine, University of Ottawa, Ottawa, ON, Canada, ⁶Faculty of Health and Applied Science, University of the West of England, Bristol, United Kingdom, ⁷Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ⁸Division of Rheumatology, Univ of Pennsylvania; Perelman School of Med, Philadelphia, PA
Background/Purpose: The need to include patients’ perspectives as key outcomes in clinical research is now widely recognized. This project was designed to describe the experience…
Abstract Number: 1306 • 2016 ACR/ARHP Annual Meeting
Magnetic Resonance Imaging Measures of Disease Activity in Rheumatoid Arthritis Patients Treated with Multiple Regimens of DMARD Therapy
Paolo Pace¹, Arthur Lau², Jonathan D. Adachi³, Matthew A. Jessome⁴, George Ioannidis² and Minta Patel⁵, ¹Rheumatology, McMaster Unversity, Hamilton, ON, Canada, ²St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada, ⁵Cambridge Memorial Hospital, Cambridge, ON, Canada
Background/Purpose: Magnetic resonance imaging ( MRI ) in rheumatoid arthritis ( RA ) has been shown to be more sensitive than clinical and radiological parameters…
Abstract Number: 1423 • 2016 ACR/ARHP Annual Meeting
Using Self-Reported Patient Experiences to Evaluate Patient Reported Outcomes (PRO) Instruments: Learnings from Digital Patient Communities in Psoriatic Arthritis
Stephen Doogan¹, John Heid², Samir Benosman³, Alexis Ogdie⁴, Layne Martin⁵, Prashanth Sunkureddi⁶ and Jacqueline Palmer⁷, ¹Real Life Sciences, New York, NY, ²Kinapse, Inc, London, United Kingdom, ³Advisory Services, Kinapse, Inc, London, United Kingdom, ⁴University of Pennsylvania, Philadelphia, PA, ⁵CreakyJoints, NY, ⁶Rheumatology, Clear Lake Rheumatology Center, Nassau Bay, TX, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Psoriatic Arthritis (PsA) is a debilitating disease with significant impact on patient quality of life (QoL). While patient reported outcome (PRO) instruments broadly capture…
Abstract Number: 1426 • 2016 ACR/ARHP Annual Meeting
Using Self-Reported Patient Experiences to Understand Patient Burden: Learnings from Digital Patient Communities in Ankylosing Spondylitis
Prashanth Sunkureddi¹, Dawn Gibson², Stephen Doogan³, John Heid⁴, Samir Benosman⁵ and Yujin Park⁶, ¹Rheumatology, Clear Lake Rheumatology Center, Nassau Bay, TX, ²The Global Healthy Living Foundation, Upper Nyack, NY, ³Real Life Sciences, New York, NY, ⁴Kinapse, Inc, London, United Kingdom, ⁵Advisory Services, Kinapse, Inc, London, United Kingdom, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Ankylosing Spondylitis (AS) is a chronic inflammatory disorder of the spinal joints that can lead to severe, chronic pain and discomfort. There is a…
Abstract Number: 1432 • 2016 ACR/ARHP Annual Meeting
The EULAR Systemic Sclerosis Impact of Disease Score – a New Patient-Reported Outcome Measure for Patients with Systemic Sclerosis Under Development
Rucsandra Dobrota¹, Mike Becker², Kim Fligelstone^3,4, Jaap Fransen⁵, Ann Kennedy⁶, Yannick Allanore⁷, Patricia Carreira⁸, László Czirják⁹, Christopher Denton¹⁰, Roger Hesselstrand¹¹, Gunnel Sandqvist¹¹, Otylia Kowal-Bielecka¹², Marco Matucci Cerinic¹³, Carina Mihai¹⁴, Ana Maria Gheorghiu¹⁵, Ulf Müller-Ladner¹⁶, Marc Frerix¹⁷, Turid Heiberg¹⁸ and Oliver Distler¹, ¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom, ⁴Federation of European Scleroderma Associations (FESCA), London, United Kingdom, ⁵Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ⁶Federation of European Scleroderma Associations (FESCA), Tournai, Belgium, ⁷Department of Rheumatology, University Paris Descartes and Cochin Hospital, Paris, France, ⁸Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁹Department of Rheumatology and Immunology, University of Pécs, Faculty of Medicine, Pécs, Hungary, ¹⁰Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ¹¹Department of Rheumatology, Lund University, Lund, Sweden, ¹²Department of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland, ¹³Department of Rheumatology, University of Florence, Florence, Italy, ¹⁴Department of Internal Medicine and Rheumatology, Carol Davila University of Medicine and Pharmacy, Cantacuzino Hospital, Bucharest, Romania, ¹⁵Carol Davila University of Medicine and Pharmacy, Internal Medicine and Rheumatology Department, Cantacuzino Clinical Hospital, Bucharest, Romania, ¹⁶Department of Internal Medicine and Rheumatology, Justus-Liebig-University Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, ¹⁷Department of Rheumatology and Clinical Immunology, Justus-Liebig-University Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, ¹⁸Department of Health and Social Sciences, Oestfold University College, Oslo, Norway
Background/Purpose: Patient reported outcome measures (PROM) are required as key outcomes in disease modifying therapeutic trials in systemic sclerosis (SSc). A PROM tool in SSc,…
Abstract Number: 1598 • 2016 ACR/ARHP Annual Meeting
Olokizumab Treatment of Both Western and Asian Patients with Rheumatoid Arthritis Who Have Failed Anti-TNF Treatment Results in Sustained Improvements in Patient-Reported Outcomes
Mark C. Genovese¹, Patrick Durez², Roy Fleischmann³, Yoshiya Tanaka⁴, Daniel E. Furst⁵, Hisashi Yamanaka⁶, Igor Vasyutin⁷, Thangavel Kaviarasu⁸, Elena Korneva⁷, Dmitry Koloda⁷ and Tsutomu Takeuchi⁹, ¹Stanford University Medical Center, Palo Alto, CA, ²Department of Rheumatology, Université Catholique de Louvain, Brussels, Belgium, ³Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ⁵David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁶Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁷R-Pharm CJSC, Moscow, Russian Federation, ⁸Quintiles Inc, Mumbai, India, ⁹School of Medicine, Keio University, Tokyo, Japan
Background/Purpose: Rheumatoid arthritis (RA) has a high patient (pt) burden with significant impact on health-related quality of life. We report the effect of treatment with…

« Previous Page
1
…
3
4
5
6
7
…
9
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].